EUVIMEDDescoperă EUVIMED
Klinische StudieMultizentrische StudieOpen access

Outcomes of Patients With High‐Risk Plaques Treated With a Bioresorbable Magnesium Scaffold: Insights From the BIOMAG‐I Study

Pablo M Rubio, Hector M Garcia-Garcia, Gebremedhin D Melaku, Eloina Baltazar, Michael Haude, Adrian Wlodarczak, René J van der Schaaf, Jan Torzewski, Bert Ferdinande, Javier Escaned, Juan F Iglesias, Johan Bennett iD and 7 more

Catheterization and Cardiovascular Interventions · 2026-08 · 108 (2) · 568-577

DOI: 10.1002/ccd.70655 ↗

At a glance

Klinische Studie in Catheterization and Cardiovascular Interventions, published online on 2026-06-07. Written by Pablo M Rubio and 18 co-authors. Institution: Interventional Cardiology, Medstar Washington Hospital Center, Washington, USA. Major MEDLINE topics: Absorbable Implants, Coronary Artery Disease, Coronary Vessels, Magnesium. 17 references. The full text is freely available in PubMed Central.

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

Background

Early identification and targeted treatment of coronary lesions at higher risk of future events remains a major unmet need in coronary artery disease research. Invasive treatment of such plaques is controversial. The third‐generation bioresorbable magnesium scaffold (DREAMS 3G) may provide a valuable alternative, but it has not been evaluated in this setting. The BIOMAG‐I study, with comprehensive OCT and IVUS imaging, offers a unique opportunity to investigate high‐risk plaque morphology and its vascular response.

Aims

We aimed to assess the association between lesions with high‐risk plaque features treated with the DREAMS 3G scaffold and late lumen loss (LLL) at follow‐up.

Methods

This post‐hoc analysis included patients with stable coronary artery disease and high‐quality intravascular imaging. High‐risk plaque was defined as μFR > 0.80 with PB ≥ 70%. Subgroups were further stratified by the presence of MLA < 4 mm², TCFA < 80 μm, lipid arc >90°, or all combined PB was assessed by IVUS or estimated by OCT when IVUS was unavailable. LLL was measured at 6 and 12 months.

Results

Of 83 patients, 42 (50.6%) met the definition of μFR > 0.80 with PB ≥ 70%. Within this cohort, 41 also had MLA < 4 mm², 23 had TCFA < 80 μm, 16 had lipid arc ≥ 180°, and 16 presented all four features. LLL remained low in the overall PB ≥ 70% group (0.21 ± 0.29 mm at 6 months; 0.27 ± 0.44 mm at 12 months) and was similarly low or even lower across the additional subgroups, including those with all features combined (0.19 ± 0.21 mm and 0.16 ± 0.19 mm).

Conclusions

In this sub‐analysis of the BIOMAG‐I trial, the DREAMS 3G bioresorbable magnesium scaffold demonstrated favorable performance, with low LLL and a low rate of clinical outcomes during the resorption period. These findings support DREAMS 3G as a promising “leave‐nothing‐behind” strategy for selected high‐risk plaques, warranting confirmation in larger prospective studies.

Subjects

MeSH terms (MEDLINE)

Absorbable ImplantsCoronary Artery DiseaseCoronary VesselsMagnesiumPercutaneous Coronary InterventionPlaque, AtheroscleroticAgedFemaleHumansMaleMiddle AgedCoronary AngiographyPredictive Value of TestsProsthesis DesignRisk AssessmentRisk FactorsTime FactorsTomography, Optical CoherenceTreatment OutcomeUltrasonography, Interventional

Author keywords

bioresorbable scaffoldhigh risk lesionsintravascular imagingintravascular ultrasoundlate lumen lossoptical coherence tomography

Substances

Magnesium

Authors and institutions

  • Interventional Cardiology, Medstar Washington Hospital Center, Washington, USA.
  • Interventional Cardiology, Antiguo Hospital Civil de Guadalajara Fran Antonio Alcalde, GDL, Jalisco, México.
  • Medical Clinic, I, Rheinland Klinikum Neuss GmbH, Lukaskrankenhaus, Neuss, Germany.
  • Division of Cardiology at the Copper Health Center Inc., Lubin, Poland.
  • Faculty of Medicine, University of Science and Technology in Wroclaw, Poland.
  • Department of Interventional Cardiology, OLVG, Amsterdam, the Netherlands.

ORCID profiles: Johan Bennett, Paul Vermeersch, Ron Waksman

Cite

APA

Rubio, P. M., Garcia-Garcia, H. M., Melaku, G. D., Baltazar, E., Haude, M., Wlodarczak, A., van der Schaaf, R. J., Torzewski, J., Ferdinande, B., Escaned, J., Iglesias, J. F., Bennett, J., Toth, G. G., Joner, M., Toelg, R., Wiemer, M., Olivecrona, G., Vermeersch, P., & Waksman, R. (2026). Outcomes of Patients With High‐Risk Plaques Treated With a Bioresorbable Magnesium Scaffold: Insights From the BIOMAG‐I Study. Catheterization and Cardiovascular Interventions, 108(2), 568-577. https://doi.org/10.1002/ccd.70655

Vancouver

Rubio PM, Garcia-Garcia HM, Melaku GD, Baltazar E, Haude M, Wlodarczak A, et al. Outcomes of Patients With High‐Risk Plaques Treated With a Bioresorbable Magnesium Scaffold: Insights From the BIOMAG‐I Study. Catheterization and Cardiovascular Interventions. 2026;108(2):568-577. doi:10.1002/ccd.70655

BibTeX
@article{Rubio2026,
  author = {Rubio, Pablo M and Garcia-Garcia, Hector M and Melaku, Gebremedhin D and Baltazar, Eloina and Haude, Michael and Wlodarczak, Adrian and van der Schaaf, René J and Torzewski, Jan and Ferdinande, Bert and Escaned, Javier and Iglesias, Juan F and Bennett, Johan and Toth, Gabor G and Joner, Michael and Toelg, Ralph and Wiemer, Marcus and Olivecrona, Göran and Vermeersch, Paul and Waksman, Ron},
  title = {Outcomes of Patients With High‐Risk Plaques Treated With a Bioresorbable Magnesium Scaffold: Insights From the BIOMAG‐I Study},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2026},
  volume = {108},
  number = {2},
  pages = {568--577},
  doi = {10.1002/ccd.70655}
}
Start for free →